» Articles » PMID: 7706276

Identification of Two Transcription Activation Units in the N-terminal Domain of the Human Androgen Receptor

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1995 Mar 31
PMID 7706276
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

To locate in detail the regions in the human androgen receptor (AR) involved in transcription activation, a series of N-terminal deletions was introduced in the wild type AR and in a constitutively active AR. The different constructs were tested for their capacity to activate transcription. Almost the entire N-terminal domain (residues 1-485) was necessary for full wild type AR activity when cotransfected with the (GRE)2tkCAT reporter in HeLa cells. In contrast, a smaller part of the N-terminal domain (amino acids 360-528) was sufficient for the constitutively active AR to induce transcription of the same (GRE)2tkCAT reporter in HeLa cells. This demonstrates the capacity of the AR to use different regions in the N-terminal domain as transcription activation units (TAUs). To obtain additional information of AR N-terminal TAUs, the GAL4 DNA binding domain was linked to either the entire or parts of the AR N-terminal domain and cotransfected with the (UAS)2tkCAT reporter in HeLa cells. The results confirmed that the first 485 amino acid residues accommodate a transcription activation function. When the chimeric AR-GAL4 constructs were tested on a different reporter ((UAS)5E1bCAT), a small shift in position of the TAU, responsible for full transcription activation, was observed. The data presented show that the size and location of the active TAU in the human AR is variable, being dependent on the promoter context and the presence or absence of the ligand binding domain.

Citing Articles

The androgen receptor amino-terminal domain: structure, function and therapeutic potential.

Hunter I, Jamieson C, McEwan I Endocr Oncol. 2025; 5(1):e240061.

PMID: 40051657 PMC: 11883864. DOI: 10.1530/EO-24-0061.


Phase Separation Mediated Sub-Nuclear Compartmentalization of Androgen Receptors.

Yavuz S, Abraham T, Houtsmuller A, van Royen M Cells. 2024; 13(20.

PMID: 39451211 PMC: 11506798. DOI: 10.3390/cells13201693.


N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.

Chen Y, Lan T Front Pharmacol. 2024; 15:1451957.

PMID: 39359255 PMC: 11444995. DOI: 10.3389/fphar.2024.1451957.


Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.

Obst J, Tien A, Setiawan J, Deneault L, Sadar M Steroids. 2024; 210:109482.

PMID: 39053630 PMC: 11364166. DOI: 10.1016/j.steroids.2024.109482.


Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.

Tien A, Sadar M Int J Mol Sci. 2024; 25(3).

PMID: 38339092 PMC: 10855698. DOI: 10.3390/ijms25031817.